Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
FDA Enforcement Actions and Safety Concerns In September 2025, the FDA issued over 50 warning letters to compounders marketing GLP-1 products as generic equivalents to FDA-approved drugs
Urinary lithogenic risk profile in recurrent stone formers with hyperoxaluria: a randomized controlled trial comparing DASH (Dietary Approaches to Stop Hypertension)-style and low-oxalate diets
121 Going forward, we need more translational studies to see whether GLP-1 receptor agonists can really improve outcomes in spinal cord injury
Cell 149 , 10601072 (2012)
US$ 29.43
US$ 26.48
US$ 26.07
US$ 20.36
US$ 27.48
